121 related articles for article (PubMed ID: 38153185)
1. Correction to 'Using energy to go downhill-a genoprotective role for ATPase activity in DNA topoisomerase II'.
Nucleic Acids Res; 2024 Feb; 52(3):1525. PubMed ID: 38153185
[No Abstract] [Full Text] [Related]
2. Using energy to go downhill-a genoprotective role for ATPase activity in DNA topoisomerase II.
Bandak AF; Blower TR; Nitiss KC; Shah V; Nitiss JL; Berger JM
Nucleic Acids Res; 2024 Feb; 52(3):1313-1324. PubMed ID: 38038260
[TBL] [Abstract][Full Text] [Related]
3. Using energy to go downhill - a genoprotective role for ATPase activity in DNA topoisomerase II.
Bandak AF; Blower TR; Nitiss KC; Shah V; Nitiss JL; Berger JM
bioRxiv; 2023 Jun; ():. PubMed ID: 37425896
[TBL] [Abstract][Full Text] [Related]
4. A topoisomerase from Escherichia coli related to DNA gyrase.
Brown PO; Peebles CL; Cozzarelli NR
Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6110-4. PubMed ID: 230498
[TBL] [Abstract][Full Text] [Related]
5. Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.
Jensen LH; Thougaard AV; Grauslund M; Søkilde B; Carstensen EV; Dvinge HK; Scudiero DA; Jensen PB; Shoemaker RH; Sehested M
Cancer Res; 2005 Aug; 65(16):7470-7. PubMed ID: 16103101
[TBL] [Abstract][Full Text] [Related]
6. Catalysis of ATP hydrolysis by two NH(2)-terminal fragments of yeast DNA topoisomerase II.
Olland S; Wang JC
J Biol Chem; 1999 Jul; 274(31):21688-94. PubMed ID: 10419479
[TBL] [Abstract][Full Text] [Related]
7. Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue.
Chène P; Rudloff J; Schoepfer J; Furet P; Meier P; Qian Z; Schlaeppi JM; Schmitz R; Radimerski T
BMC Chem Biol; 2009 Jan; 9():1. PubMed ID: 19128485
[TBL] [Abstract][Full Text] [Related]
8. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
[TBL] [Abstract][Full Text] [Related]
9. Clarifying the Mechanism of Copper(II) α-(N)-Heterocyclic Thiosemicarbazone Complexes on DNA Topoisomerase IIα and IIβ.
Keck JM; Conner JD; Wilson JT; Jiang X; Lisic EC; Deweese JE
Chem Res Toxicol; 2019 Oct; 32(10):2135-2143. PubMed ID: 31512855
[TBL] [Abstract][Full Text] [Related]
10. Discovery of new ATP-competitive inhibitors of human DNA topoisomerase IIα through screening of bacterial topoisomerase inhibitors.
Skok Ž; Durcik M; Gramec Skledar D; Barančoková M; Peterlin Mašič L; Tomašič T; Zega A; Kikelj D; Zidar N; Ilaš J
Bioorg Chem; 2020 Sep; 102():104049. PubMed ID: 32688116
[TBL] [Abstract][Full Text] [Related]
11. Examination of the Impact of Copper(II) α-(N)-Heterocyclic Thiosemicarbazone Complexes on DNA Topoisomerase IIα.
Wilson JT; Jiang X; McGill BC; Lisic EC; Deweese JE
Chem Res Toxicol; 2016 Apr; 29(4):649-58. PubMed ID: 26982206
[TBL] [Abstract][Full Text] [Related]
12. Amide I'-II' 2D IR spectroscopy provides enhanced protein secondary structural sensitivity.
Deflores LP; Ganim Z; Nicodemus RA; Tokmakoff A
J Am Chem Soc; 2009 Mar; 131(9):3385-91. PubMed ID: 19256572
[TBL] [Abstract][Full Text] [Related]
13. Mode-specific vibrational energy relaxation of amide I' and II' modes in N-methylacetamide/water clusters: intra- and intermolecular energy transfer mechanisms.
Zhang Y; Fujisaki H; Straub JE
J Phys Chem A; 2009 Apr; 113(13):3051-60. PubMed ID: 19320512
[TBL] [Abstract][Full Text] [Related]
14. HU-331 is a catalytic inhibitor of topoisomerase IIα.
Regal KM; Mercer SL; Deweese JE
Chem Res Toxicol; 2014 Dec; 27(12):2044-51. PubMed ID: 25409338
[TBL] [Abstract][Full Text] [Related]
15. ATPase domain of eukaryotic DNA topoisomerase II. Inhibition of ATPase activity by the anti-cancer drug bisdioxopiperazine and ATP/ADP-induced dimerization.
Hu T; Sage H; Hsieh TS
J Biol Chem; 2002 Feb; 277(8):5944-51. PubMed ID: 11850431
[TBL] [Abstract][Full Text] [Related]
16. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
[TBL] [Abstract][Full Text] [Related]
17. Redesigning the type II' β-turn in green fluorescent protein to type I': implications for folding kinetics and stability.
Madan B; Sokalingam S; Raghunathan G; Lee SG
Proteins; 2014 Oct; 82(10):2812-22. PubMed ID: 25044033
[TBL] [Abstract][Full Text] [Related]
18. Probing the structural determinants of type II' beta-turn formation in peptides and proteins.
Gibbs AC; Bjorndahl TC; Hodges RS; Wishart DS
J Am Chem Soc; 2002 Feb; 124(7):1203-13. PubMed ID: 11841288
[TBL] [Abstract][Full Text] [Related]
19. The p53 tumor suppressor stimulates the catalytic activity of human topoisomerase IIalpha by enhancing the rate of ATP hydrolysis.
Kwon Y; Shin BS; Chung IK
J Biol Chem; 2000 Jun; 275(24):18503-10. PubMed ID: 10764786
[TBL] [Abstract][Full Text] [Related]
20. HU-331 and Oxidized Cannabidiol Act as Inhibitors of Human Topoisomerase IIα and β.
Wilson JT; Fief CA; Jackson KD; Mercer SL; Deweese JE
Chem Res Toxicol; 2018 Feb; 31(2):137-144. PubMed ID: 29272108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
